PCM
CCCC icon

Prelude Capital Management’s C4 Therapeutics CCCC Stock Holding History

Prelude Capital Management’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$81.4K Buy
+30,957
New +$72.9K 0.01% 1081
2024
Q1 		– Sell
-17,749
Closed -$100K – 1331
2023
Q4 		$100K Sell
17,749
-33,400
-65% -$76.2K 0.01% 1026
2023
Q3 		$95.1K Buy
51,149
+17,149
+50% +$52.3K 0.01% 1000
2023
Q2 		$93.5K Buy
+34,000
New +$109K 0.01% 938

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Prelude Capital Management's CCCC Position: Q1 2026 in Review

Prelude Capital Management opened a new position in C4 Therapeutics (CCCC) in Q1 2026: 30,957 shares worth $81.4K. The stake represents 0.01% of the portfolio and ranks #1081 among its holdings. This is a return to the name: Prelude Capital Management previously reported a position in CCCC as recently as Q4 2023.

Prelude Capital Management first reported a position in CCCC in Q2 2023 and has held it in 4 quarters since. The position peaked at $100K in Q4 2023. 123 funds tracked by Wall St. Rank hold CCCC as of Q1 2026.

  • Prelude Capital Management held 30,957 shares of C4 Therapeutics worth $81.4K as of Q1 2026.
  • C4 Therapeutics was a new Prelude Capital Management position in Q1 2026.
  • C4 Therapeutics made up 0.01% of Prelude Capital Management's portfolio in Q1 2026, its #1081 holding.
  • Prelude Capital Management first reported a position in C4 Therapeutics in Q2 2023 and has held it in 4 quarters since.
  • Prelude Capital Management's C4 Therapeutics position peaked at $100K in Q4 2023.
  • 123 funds tracked by Wall St. Rank held C4 Therapeutics as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.